Treating C3 glomerulopathy with eculizumab [PDF]
BMC Nephrology, 2018 Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade ...
Thomas Welte +7 more
doaj +2 more sources
Eculizumab‐related drug reaction in a patient with neuromyelitis optica [PDF]
Clinical Case Reports, 2023 Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of
Rishi Sharma, Moises Romo, Flavia Nelson
doaj +2 more sources
Eculizumab as Additional Rescue Therapy in Myasthenic Crisis [PDF]
MusclesEculizumab is a monoclonal antibody blocking the terminal complement protein C5. As demonstrated in the phase III randomized, placebo-controlled, REGAIN clinical trial, eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive ...
Francesco Crescenzo +8 more
doaj +2 more sources
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome [PDF]
Clinical Pharmacology: Advances and Applications, 2011 Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj +3 more sources
Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue). [PDF]
, 2021 Cumulative survival (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).
Hong Si Nga (4592092) +9 more
core +1 more source
Comparison of demographic and outcome in the Brazilian aHUS cohort patients according to the treatment (without the use of Eculizumab, prophylactic Eculizumab, and Eculizumab treatment). [PDF]
, 2021 Comparison of demographic and outcome in the Brazilian aHUS cohort patients according to the treatment (without the use of Eculizumab, prophylactic Eculizumab, and Eculizumab treatment).
Hong Si Nga (4592092) +9 more
core +1 more source
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria [PDF]
, 2021 Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease characterized by chronic complement-mediated hemolysis. C5 inhibition controls intravascular hemolysis in untreated PNH but cannot address extravascular hemolysis ...
Kiladjian, Jean-Jacques +18 more
core +4 more sources
Aplicaciones terapéuticas del eculizumab [PDF]
, 2022 Introducción: El eculizumab es un anticuerpo monoclonal de tipo IgG diseñado para el tratamiento de la hemoglobinuria paroxística nocturna (HPN), en el que su diana farmacológica forma parte del sistema del complemento.
Campos González, Natalia +7 more
core +1 more source
Cumulative incidence of TMA graft loss (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue). [PDF]
, 2021 Cumulative incidence of TMA graft loss (days) in the Brazilian aHUS cohort patients divided by groups: Not received eculizumab (red), prophylactic eculizumab (green), and eculizumab treatment (blue).
Hong Si Nga (4592092) +9 more
core +1 more source
Eculizumab in Pediatric Kidney Disorders: A Review: Eculizumab in Kidney Disorders [PDF]
, 2022 Eculizumab is a humanized monoclonal antibody targeting the C5 (complement 5) memberof complement proteins and inhibiting its cleavage to C5a and C5b. Eculizumab has beenproven to be effective in a wide array of nephrologic, neurologic, and hematologic ...
Mohkam, Masoumeh +6 more
core +1 more source